One of the most successful cancer immunotherapies is immune checkpoint blockade therapy, such as anti-PD-1, which blocks the intercellular communication between PD-L1 expressed on tumor cells or antigen presenting cells and PD-1 expressed on T cells, and reactivate the ability of T cells to identify and eliminate tumor cells. This evidence concerns the gene CD274 and neoplasm.